PriceTargets.com logo

SCYNEXIS - SCYX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.00
  • Forecasted Upside: 867.74%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.55 As of 04/23/2024 01:00 AM ET
▲ +0.11 (7.64%)

This chart shows the closing price for SCYX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New SCYNEXIS Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SCYX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SCYX

Analyst Price Target is $15.00
▲ +867.74% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for SCYNEXIS in the last 3 months. The average price target is $15.00, with a high forecast of $15.00 and a low forecast of $15.00. The average price target represents a 867.74% upside from the last price of $1.55.

This chart shows the closing price for SCYX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in SCYNEXIS. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/1/2024Cantor FitzgeraldReiterated RatingOverweightLow
1/12/2024Cantor FitzgeraldReiterated RatingOverweightLow
12/18/2023Cantor FitzgeraldReiterated RatingOverweightLow
8/15/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$15.00Low
4/3/2023GuggenheimBoost TargetBuy$8.00 ➝ $9.00Low
4/3/2023LADENBURG THALM/SH SHReiterated RatingBuy$15.00Low
3/30/2023Maxim GroupBoost Target$7.00 ➝ $10.00Low
2/28/2023GuggenheimInitiated CoverageBuy$8.00Low
10/25/2022Maxim GroupLower Target$11.00 ➝ $7.00Low
10/21/2022Brookline Capital AcquisitionReiterated RatingBuy$8.00Low
5/13/2022HC WainwrightLower Target$14.00 ➝ $8.00High
3/31/2022HC WainwrightLower TargetBuy$20.00 ➝ $14.00Medium
8/24/2021Brookline Capital ManagementReiterated RatingBuyLow
6/30/2021HC WainwrightReiterated RatingBuy$20.00Medium
6/7/2021AegisLower TargetBuy$40.00 ➝ $35.00Low
6/3/2021HC WainwrightReiterated RatingBuyMedium
5/18/2021HC WainwrightReiterated RatingBuyHigh
4/12/2021AegisLower TargetBuy$45.00 ➝ $40.00High
2/17/2021Maxim GroupBoost TargetBuy$17.00 ➝ $22.00Low
2/15/2021AegisReiterated RatingBuyHigh
1/22/2021GuggenheimInitiated CoverageBuy$25.00High
1/5/2021Cantor FitzgeraldInitiated CoverageOverweight$30.00N/A
12/28/2020HC WainwrightLower TargetBuy$35.00 ➝ $20.00N/A
12/23/2020Maxim GroupReiterated RatingBuy$17.00N/A
11/6/2020Maxim GroupReiterated RatingBuy$15.00High
8/11/2020LADENBURG THALM/SH SHReiterated RatingBuy$25.00High
8/10/2020Needham & Company LLCInitiated CoverageBuy$50.00High
7/15/2020Needham & Company LLCReiterated RatingBuy$50.00High
5/31/2020AegisReiterated RatingBuy$45.00High
5/19/2020HC WainwrightReiterated RatingBuy$35.00Medium
5/11/2020Needham & Company LLCReiterated RatingBuy$50.00Low
4/23/2020AegisBoost TargetBuy$40.00 ➝ $45.00High
4/22/2020Maxim GroupReiterated RatingBuy$40.00Medium
4/22/2020HC WainwrightReiterated RatingBuy$35.00High
4/21/2020Needham & Company LLCInitiated CoverageBuy$50.00High
3/12/2020Maxim GroupReiterated RatingBuy$40.00High
2/14/2020LADENBURG THALM/SH SHReiterated RatingBuyHigh
1/9/2020HC WainwrightReiterated RatingBuy$35.00Low
1/9/2020LADENBURG THALM/SH SHReiterated RatingBuy$60.00Medium
12/16/2019HC WainwrightReiterated RatingBuy$35.00Low
11/7/2019Needham & Company LLCReiterated RatingBuy$50.00Low
11/5/2019LADENBURG THALM/SH SHReiterated RatingBuy$60.00Low
10/18/2019Needham & Company LLCSet TargetBuy$50.00Low
8/19/2019Brookline Capital ManagementReiterated RatingBuyHigh
8/12/2019Needham & Company LLCReiterated RatingBuy$50.00Low
7/31/2019AegisInitiated CoverageBuyMedium
7/24/2019Maxim GroupSet TargetBuy$40.00Low
5/24/2019LADENBURG THALM/SH SHSet TargetBuy$60.00Low
5/12/2019Needham & Company LLCReiterated RatingBuy$50.00Medium
(Data available from 4/23/2019 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2023
  • 1 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/26/2023
  • 5 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
11/25/2023
  • 5 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
12/25/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/24/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2024

Current Sentiment

  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

SCYNEXIS logo
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Read More

Today's Range

Now: $1.55
Low: $1.48
High: $1.61

50 Day Range

MA: $1.58
Low: $1.39
High: $1.82

52 Week Range

Now: $1.55
Low: $1.35
High: $3.87

Volume

151,695 shs

Average Volume

200,351 shs

Market Capitalization

$58.51 million

P/E Ratio

1.17

Dividend Yield

N/A

Beta

1.57

Frequently Asked Questions

What sell-side analysts currently cover shares of SCYNEXIS?

The following Wall Street sell-side analysts have issued research reports on SCYNEXIS in the last year: Cantor Fitzgerald, StockNews.com, and TheStreet.
View the latest analyst ratings for SCYX.

What is the current price target for SCYNEXIS?

1 Wall Street analysts have set twelve-month price targets for SCYNEXIS in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 867.7%. Cantor Fitzgerald has the highest price target set, predicting SCYX will reach $15.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $15.00 for SCYNEXIS in the next year.
View the latest price targets for SCYX.

What is the current consensus analyst rating for SCYNEXIS?

SCYNEXIS currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SCYX will outperform the market and that investors should add to their positions of SCYNEXIS.
View the latest ratings for SCYX.

What other companies compete with SCYNEXIS?

Other companies that are similar to SCYNEXIS include Immuneering, Homology Medicines, Reneo Pharmaceuticals, Gain Therapeutics and Vaxxinity. Learn More about companies similar to SCYNEXIS.

How do I contact SCYNEXIS's investor relations team?

SCYNEXIS's physical mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company's listed phone number is (201) 884-5485 and its investor relations email address is [email protected]. The official website for SCYNEXIS is www.scynexis.com. Learn More about contacing SCYNEXIS investor relations.